Learning CNS immunopathology from therapeutic interventions-Reference-Cited by-同舟云学术

Learning CNS immunopathology from therapeutic interventions

Published:2023-11-08 Issue:721 Volume:15 Page:
ISSN:1946-6234
Container-title:Science Translational Medicine
language:en
Short-container-title:Sci. Transl. Med.

Author:

Schwab Nicholas¹^ORCID,Wiendl Heinz¹²^ORCID

Affiliation:

1. Department of Neurology with Institute of Translational Neurology, University of Muenster, Muenster 48149, Germany.

2. Brain and Mind Centre, University of Sydney, Camperdown NSW 2050, Australia.

Abstract

Modulation of immune cell trafficking across the blood-brain barrier has not only introduced a therapeutic avenue for multiple sclerosis (MS) but also represents an example of reverse translational medicine. Data from clinical trials of drugs such as natalizumab and fingolimod have revealed the involvement of different compartments in relapsing versus non-relapsing MS immune biology, contributed to our understanding of central nervous system (CNS) immune surveillance, and stimulated new fields of research. Here, we discuss the results of these trials, as well as patient biomaterial-based scientific projects, and how both have informed our understanding of CNS immunopathology.

Publisher

American Association for the Advancement of Science (AAAS)

Subject

General Medicine

Link

https://www.science.org/doi/pdf/10.1126/scitranslmed.adg7863

Reference74 articles.

1. Astrocyte–endothelial interactions at the blood–brain barrier

2. Capture, crawl, cross: the T cell code to breach the blood–brain barriers

3. Human CCR5high effector memory cells perform CNS parenchymal immune surveillance via GZMK-mediated transendothelial diapedesis

4. Three or more routes for leukocyte migration into the central nervous system

5. IMMUNOLOGY OF MULTIPLE SCLEROSIS